Experts Discuss the Pathophysiology, Diagnosis, and Treatment of BPD…

MyCancerHaven

R. Vij, G. Murthy

Clinical Applications of ctDNA in Breast Cancer Diagnosis and Manage…

University of Miami Sylvester Comprehensive Cancer Center

D. Tripathy

ESMO 2024 Summary: The Emerging Global Epidemic of Early-Onset Cance…

2024 ESMO Annual Meeting Insights Hub

S. Ogino

Understanding the NPM1 Mutation in AML: Dr. Jekyll and Mr. Hyde

SOHO Brazil 2024

J. Lancet

Where I Use Azacitidine and Venetoclax in AML: Present and Future

SOHO Brazil 2024

J. Lancet

Visible vs. Invisible Cancers - The Genomics and Natural History

Laurence Klotz

Cancer Genomics: Molecular Profile Interpretation 101

Total Health

L. Welch

Treatment of AML: Managing the Patient When Transplant Is Not an Opt…

Indy Hematology Review

H. Erba

Administration and Dosing of Tagraxofusp for BPDCN

Emanuele Angelucci

ASH 2024 Summary: Transplant Options and Outcomes for TP53 Myeloid D…

2024 ASH Annual Meeting Insights Hub

H. Fernandez

Current Treatment of Younger 1L AML in 2024

Gautam Borthakur

ASCO® 2024 Precision Medicine Highlights: LAURA and CROWN Trials (NS…

2024 ASCO® Annual Meeting Insights Hub

V. Subbiah

BPDCN: Current and Future Directions

Icahn School of Medicine at Mount Sinai

N. Pemmaraju

2024 Updates in AML

University of Colorado Division of Hematology

C. McMahon

Secondary AML: Best Therapy Options

Weill Cornell Medicine Oncology & Hematology

P. Desai

ASH 2024 Insights: Venetoclax + Aza for 1L Younger AML Pts Independe…

2024 ASH Annual Meeting Insights Hub

J. Watts

Clinical Implications of Tumor Agnostic Therapies

Shivaani Kummar

History of Cancer and Its Treatment: What Will It Take to Cure?

University of Colorado Cancer Center

C. Lieu

EHA 2024 Insights: Real-World Data From R/R BPDCN Treated With Tagra…

Insights from 2024 EHA Annual Meeting

E. Angelucci

Current Treatment Landscape in BPDCN

Cristina Papayannidis